price month
despit posit vumer gi data biogen
announc top-line result phase trial
vumer gener toler associ fewer gi
compar tecfidera result in-lin
expect gener expect investor recal vumer
diroximel fumar design rapidli convert monomethyl fumar
referenc tecfidera dimethyl fumar part
regulatori pathway continu believ enhanc gi toler
profil sell point drug significantli compel enough
attract bolu switcher agent multipl sclerosi
physician survey respond report lowest level familiar
enthusiasm vumer rel ms drug develop lack
prescrib awar intensifi competit oral space
novel expect gener aubagio gilenya lead us take
conserv view vumer commerci potenti forecast
sale reiter under-perform tp
ms franchis unlik drive growth near-term concern ip threat
tecfidera still consid biggest near-term threat upcom
ipr court challeng tecfidera ip lose ip
protect could significantli impact npv tecfidera proprietari
ms survey work note takeaway thought outcom
tecfidera ipr note detail
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
studi result vumer better toler tecfidera measur primari
endpoint self-report day gi symptom intens score individu
gastrointestin symptom impact scale igisi week treatment
common advers event report studi
treatment group flush diarrhea nausea
vumer tecfidera vumer also associ
lower rate discontinu due gi tecfidera vs
charl martineau pm univers toronto compani mention price
